In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though.

Immunomedics, based in Morris Plains, New Jersey, is a bit of a peculiarity in the biopharma industry. Notably, it was founded in 1982, almost forty years ago, and doesn’t have a commercial product on the market. But that appears likely to soon change.

Krystal Biotech is confident enough about its pipeline of candidates of gene therapies for treating skin diseases that has started work on a new commercial manufacturing facility. It has even given it a name.

OncoCyte president and CEO Ron (Ronnie) Andrews discussed the company’s recent acquisitions and expansion of its diagnostics menu with GEN Edge . . .

Horizon 2020, the European Union’s research and innovation programme, is entering its final year. But how has the money been used to drive pharma developments in the region? We round up the most successful and innovative projects to emerge from scheme.

This week the publishing of data on Cue Biopharma’s star immunotherapy molecule, Cue 101, revealed just how much reality there is to concept. A paper published in Clinical Cancer Research on Tuesday showed research demonstrating the ability of a biologic immunotherapy drug candidate named CUE-101 to activate tumor antigen-specific antitumor immunity.